Clinical

New prescription for loop diuretic improves 30-day heart failure outcomes


 

Background: In patients with heart failure, loop diuretics are used to manage symptoms. However, the effect of loop diuretics on morbidity and mortality is not well studied.

Dr. Peter Wallenhorst

Study design: Retrospective matched cohort study.

Setting: OPTIMIZE-HF registry.

Synopsis: Using the data from the OPTIMIZE-HF registry to develop a matched cohort of 2,191 pairs of patients, researchers showed that patients hospitalized for heart failure who were not previously taking any diuretic had significantly better 30-day clinical outcomes if they were discharged on a loop diuretic. Specifically, a loop diuretic on discharge resulted in a lower 30-day all-cause mortality (hazard ratio, 0.73; 95% CI, 0.57-0.94; P = .016) and a lower risk of 30-day heart failure readmission (HR, 0.79; 95% CI, 0.63-0.99; P = .037), compared with patients not discharged on a loop diuretic.

Neither of these associations was statistically significant during a 60-day follow-up, and the authors acknowledge that significant 30-day associations may be sensitive to an unmeasured confounder.

Bottom line: Starting an outpatient loop diuretic on discharge for patients hospitalized for heart failure improves 30-day all-cause mortality and lowers the risk of 30-day heart failure readmission.

Citation: Faselis C et al. Loop diuretic prescription and 30-day outcomes in older patients with heart failure. J Am Coll Cardiol. 2020;76:669-79.

Dr. Wallenhorst is a hospitalist and palliative medicine physician at the Lexington (Ky) VA Health Care System.

Recommended Reading

Top 10 things to know about the AHA ACLS 2020 updates
The Hospitalist
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
The Hospitalist
Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems
The Hospitalist
Cardiogenic shock teams again tied to lower mortality
The Hospitalist
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
The Hospitalist
Is AFib a stroke cause or innocent bystander? The debate continues
The Hospitalist
New reports help nail down myocarditis risk with COVID-19 vaccine
The Hospitalist
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
The Hospitalist
Omega-3s tame inflammation in elderly COVID-19 patients
The Hospitalist
No benefit from lower temps for out-of-hospital cardiac arrest
The Hospitalist
   Comments ()